At a glance
ClinicalIndex Comparison RecordPhase 3Active· 404 target
Drug / intervention
PM8002 +2 moredrug
Likely dose
Paclitaxel 175mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-lable, Randomized Phase III Study of PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
In Brief
A Phase 3 clinical trial evaluating PM8002, Paclitaxel, and 1 other intervention for SCLC. Active but no longer recruiting, targeting 404 participants across 45 sites.
Detailed Summary
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with Paclitaxel as second-line treatment for SCLC
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSCLC
CountriesChina
Collaborators--
Timeline
Phase 3Active
20252026202720282029
First PostedSep 2024
Enrollment StartNov 2024
TodayJul 2026
Primary CompletionJan 2027
Study CompletionDec 2028
First PostedSep 27, 2024
Enrollment StartNov 13, 2024
Primary CompletionJan 25, 2027
Study CompletionDec 25, 2028
TodayJul 1, 2026
Enrollment to primary: 2.2 yearsPosted 1.8 years agoPrimary completion in 7 months
Interventions
PM8002drug
Following a predefined dose and date.
Paclitaxeldrug
175mg/m2 via IV infusion on Day 1 Q3W
Topotecandrug
1.25mg/m2/day via IV infusion on Days 1-5 Q3W